Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers

Kitro, Amonrphat; Sirikul, Wachiranun; Thongkum, Weeraya; Soponpong, Suthinee; Yasamut, Umpa; Kiratipaisarl, Wuttipat; Kosai, Apiradee; Kasinrerk, Watchara; Tayapiwatana, Chatchai; Srithanaviboonchai, Kriengkrai

doi:10.1016/j.vaccine.2022.04.020

Cited by 7 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Thailand, the vaccine regimen for HCWs was two doses of CoronaVac, followed by a booster dose of BNT162b2. The comparative antibody titer of pre- versus post-BNT162b2 was reported in our former study [ 37 ]. Although the antibody titers are higher in post-BNT162b2, certain populations achieved low-to-moderate responding degree ( Figure 1 ).…”

Section: Discussionmentioning

confidence: 96%

The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant

Thongkum

Thongheang

Tayapiwatana

2022

CIMB

Self Cite

View full text Add to dashboard Cite

Concerns over vaccine efficacy after the emergence of the SARS-CoV-2 Delta variant prompted revisiting the vaccine design concepts. Monoclonal antibodies (mAbs) have been developed to identify the neutralizing epitopes on spike protein. It has been confirmed that the key amino acid residues in epitopes that induce the formation of neutralizing antibodies do not have to be on the receptor-binding domain (RBD)- angiotensin-converting enzyme 2 (ACE2) contact surface, and may be conformationally hidden. In addition, this epitope is tolerant to amino acid mutations of the Delta variant. The antibody titers against RBD in health care workers in Thailand receiving two doses of CoronaVac, followed by a booster dose of BNT162b2, were significantly increased. The neutralizing antibodies against the Delta variant suggest that the overall neutralizing antibody level against the Wuhan strain, using the NeutraLISA, was consistent with the levels of anti-RBD antibodies. However, individuals with moderate anti-RBD antibody responses have different levels of a unique antibody population competing with a cross-neutralizing mAb clone, 40591-MM43, determined by in-house competitive ELISA. Since 40591-MM43 mAb indicates cross-neutralizing activity against the Delta variant, this evidence implies that the efficiency of the vaccination regimen should be improved to facilitate cross-protective antibodies against Delta variant infections. The RBD epitope recognized by 40591-MM43 mAb is hidden in the close state.

show abstract

Section: Discussionmentioning

confidence: 96%

The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant

Thongkum

Thongheang

Tayapiwatana

2022

CIMB

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even though the COVID-19 vaccines are safe (12), few local and systemic reactions were reported after the first and second doses of vaccination (13) and after the application of a heterologous booster dose among HCWs (14). Regarding the homologous versus heterologous booster, the latter demonstrated a slightly higher rate of adverse events in HCW (15).…”

Section: Of 12mentioning

confidence: 99%

Safety Profile of Standard and Booster Covid-19 Vaccines in Physicians in Quito-Ecuador. A Cross-Sectional Study

Flores-Lastra¹,

Dueñas²,

Fuenmayor-González³

et al. 2023

Preprint

View full text Add to dashboard Cite

More than 600 Healthcare workers died due to COVID-19 infection until January 2022 in Ecuador. Even though the COVID-19 vaccines are safe, local, and systemic reactions were reported among physicians. This study aims to analyze the Adverse events (AEs) of COVID-19 vaccines with an emphasis on homologous and heterologous booster doses. An electronic survey was performed in Quito- Ecuador, directed to physicians who were vaccinated with the three doses of COVID-19 vaccines. 210 participants were analyzed after administering any doses of the vaccines. At least one AE was identified in 60.0% (126/210) of the sample after the first dose, 52.40% (110/210) after the second dose, and 75.2% (158/210) after the booster dose. The most frequent AEs were localized pain, myalgia, headache, and fever. At least one drug was used in 44.3% of the population after the first dose, 37.1% after the second dose, and 63.8% in the booster dose. Heterol-ogous booster produces more AEs compared with homologous booster (80.1% vs. 53.8%), and 77.3% of participants reported that interfered with daily activities. Similar studies agree that reactogenicity occurs mainly with heterologous vaccination compared to ho-mologous vaccination. This situation affected physicians’ performance in daily activities and led them to use medication for the symptoms

show abstract

“…A three-dose vaccination regime was as efficient against the Omicron variant as a two-dose was against wild SARS-CoV-2 [20] . Several studies demonstrated that complete or fractional heterologous boosters with mRNA and adenoviral vector provided a stronger humoral response than homologous regimes [20] , [21] , [22] , [23] . Though, these studies evaluated populations primarily vaccinated with BNT and ChAd.…”

Section: Introductionmentioning

confidence: 99%

“…Limited reports described the humoral response of mRNA vaccines following inactivated virus formulations. Kitro et al found a significant increase in antibody levels among participants who received a BNT booster dose after two doses of CV [22] . The BBIBP vaccine was widely used in Peru, and, as of today, it is mainly recognized in Latin America, Asia, and Africa [24] .…”

Section: Introductionmentioning

confidence: 99%

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

et al. 2023

View full text Add to dashboard Cite

Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers

Cited by 7 publications

References 35 publications

The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant

The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant

Safety Profile of Standard and Booster Covid-19 Vaccines in Physicians in Quito-Ecuador. A Cross-Sectional Study

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

Contact Info

Product

Resources

About